This announcement is a separate document:
海普瑞：安永华明会计师事务所（特殊普通合伙）就深圳证券交易所《关于对深圳市海普瑞药业集团股份有限公司2023年年报的问询函》涉及财务报表项目问询意见的专项说明
Hyperui: Special explanation from Ernst & Young Huaming Certified Public Accountants (Special General Partnership) on the Shenzhen Stock Exchange's “Inquiry Letter on the 2023 Annual Report of Shenzhen Haipuri Pharmaceutical Group Co., Ltd.” involving fina
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.